Nature Medicine: Semaglutide in HFpEF Across Obesity Class and by Body Weight Reduction: a Prespecified Analysis of the STEP-HFpEF Trial

The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing worldwide, and there are few effective treatments.

Dr. Mikhail Kosiborod, cardiologist and vice president for research at Saint Luke’s Mid America Heart Institute, was the lead author of the STEP-HFpEF trial.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Read the full article in Nature Medicine: Semaglutide in HFpEF Across Obesity Class and by Body Weight Reduction: a Prespecified Analysis of the STEP-HFpEF Trial